Evidence map›Paper›PMID 20468046›Full record

ReviewGlia2010

Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas.

Nephi Stella

Abstract readReview
In one paragraph

Review in Glia, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 260 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
260citing papers in PubMed, 2 pooled it
24.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

260 citing papers in PubMed, 2 syntheses or guidelines pooled it, 511 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Overlapping pathways of migraine and the endocannabinoid system: Potential therapeutic targets.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026
    Review
  10. Non-neuronal targets for migraine therapy.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026
    Review
  11. Article
  12. Review
  13. Canonical Cannabinoid Receptors.Current topics in behavioral neurosciences · 2026
    Review
  14. Ageing, Neurodegeneration and the Endocannabinoid System.Current topics in behavioral neurosciences · 2026
    Review
  15. Depression of synaptic outputs by reduction of CaFrontiers in molecular neuroscience · 2026
    Article
  16. Article
  17. Review
  18. Review
  19. The Role and Mechanisms of G protein-coupled receptors in Parkinson's disease.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025
    Review
  20. Review

200 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Nephi StellaDepartment of Pharmacology, Psychiatry and Behavioral Sciences, University of Washington, Seattle, Washington 98195-7280, USA. nstella@u.washington.edu
University of Washington · US

Funding

Cannabinoid Signaling System in Microglial CellsR01DA014486 · NIDA · UNIVERSITY OF WASHINGTON · PI STELLA, NEPHI · 2001 to 2016
$4.2M
Novel CB ReceptorsR01DA021285 · NIDA · UNIVERSITY OF WASHINGTON · PI STELLA, NEPHI · 2007 to 2010
$1.2M
NIDA NIH HHS DA 14486NIDA NIH HHS DA 21285NIDA NIH HHS R01 DA014486NIDA NIH HHS R01 DA021285
6 · The paper itself

Abstract

CB1 and CB2 receptors are activated by a plethora of cannabinoid compounds, be they endogenously-produced, plant-derived or synthetic. These receptors are expressed by microglia, astrocytes and astrocytomas, and their activation regulates these cells' differentiation, functions and viability. Recent studies show that glial cells also express cannabinoid-like receptors, and that their activation regulates different cell functions, but also control cell viability. This review summarizes this evidence, and discusses how selective compounds targeting cannabinoid-like receptors constitute promising therapeutics to manage neuroinflammation and eradicate malignant astrocytomas. Importantly, the selective targeting of cannabinoid-like receptors should provide therapeutic relieve without inducing the typical psychotropic effects and possible addictive properties associated with the use of Delta9-tetrahydrocannabinol, the main psychotropic ingredient produced by the plant Cannabis sativa.

Indexed as

AnimalsAstrocytesAstrocytomaCannabinoidsHumansMicrogliaModels, NeurologicalReceptor, Cannabinoid, CB1Receptor, Cannabinoid, CB2Receptors, Cell SurfaceCannabinoidsReceptor, Cannabinoid, CB1Receptor, Cannabinoid, CB2Receptors, Cell Surface

Identifiers

PMID20468046
PMCPMC2919281
OpenAlexW2092535327

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.